Alexo Therapeutics

ALX Oncology (formerly Alexo Therapeutics) is a clinical-stage immuno-oncology company focused on developing next-generation therapies that block the CD47 checkpoint pathway. The company's lead product candidate, evorpacept (ALX148), is a high-affinity CD47 blocker designed with an inactive Fc domain to minimize hematologic toxicities, such as anemia and thrombocytopenia, which are common with other CD47-targeted agents. ALX Oncology is evaluating evorpacept in combination with various anti-cancer agents, including monoclonal antibodies and antibody-drug conjugates, across multiple solid tumor and hematologic indications. Key clinical programs include trials for gastric cancer, head and neck squamous cell carcinoma, and myelodysplastic syndromes. By leveraging its proprietary protein engineering platform, the company aims to enhance the innate and adaptive immune response against cancer.